Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EI-001 in healthy volunteers
NCT04994912Phase 1Completed
- Start
- Oct 2021
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Vitiligo and hemophagocytic lymphohistiocytosis (HLH) comparing EI-001 with Placebo (2 arms). Primary endpoint: Safety assessment at Day 1. Started Oct 2021; status: completed.
02
Drugs
EI-001
03
Conditions
Vitiligohemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT04994912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994912.